Adimab vs Theradaptive

Adimab vs Theradaptive, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adimab is on 53/100 and Theradaptive on 45/100.

Adimab logo
AdimabAdimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform.
Try Adimab
Theradaptive logo
TheradaptiveBiotech company developing targeted regenerative therapeutics using a proprietary protein engineering platform for tissue repair.
Try Theradaptive

Where each one leads

Adimab

  • our overall score: 53/100 against 45/100
  • domain rating: 39/100 against 28/100
  • headcount: 139 against 31
  • funding raised: $105M against $32.2M

Theradaptive

  • agent readiness: 47/100 against 40/100

At a glance

MeasureAdimabTheradaptive
What it isAdimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform.Biotech company developing targeted regenerative therapeutics using a proprietary protein engineering platform for tissue repair.
CategoryBiotech, Drug Discovery, Antibody Discovery, Therapeutic AntibodiesBiotech, Regenerative Medicine, Protein Engineering, Medical Devices
Sells toBusiness modelB2BB2B
OfferingPlatformPlatform
Founded20072017
HeadquartersLebanon, United StatesFrederick, United States
StatusActiveActive

Size, funding and growth

MeasureAdimabTheradaptive
Employees13931
Total funding$105M$32.2M
Latest roundSeries BSeries A
LinkedIn followers8,423Not published

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureAdimabTheradaptive
StartupHub scoreOur 0-100 rating53/10045/100
Traction60/10053/100
Search visibility20/1002/100
Quality68/10058/100
Agent readinessHow well an AI agent can read and act on the siteD (40/100)D (47/100)
Domain ratingLink authority, 0-10039/10028/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureAdimabTheradaptive
HostingAWSSelf Managed
CMSWordPressWordPress
FrameworksJquery, BootstrapJquery, Bootstrap
AnalyticsGoogle Tag Manager, Linkedin InsightGoogle Analytics 4
Support stackHubSpotNot detected

Adimab vs Theradaptive: common questions

Which is better, Adimab or Theradaptive?

On our 0-100 score Adimab rates higher (53/100 against 45/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.

How do Adimab and Theradaptive compare on the numbers?

Adimab leads on our overall score (53/100 against 45/100), domain rating (39/100 against 28/100), headcount (139 against 31), funding raised ($105M against $32.2M). Theradaptive leads on agent readiness (47/100 against 40/100).

Read the full Adimab review and pricing or the Theradaptive review and pricing. You can also browse other Adimab alternatives we track.